Immune checkpoint inhibitors plus anti-angiogenesis in patients with resected high-risk hepatitis B virus-associated hepatocellular carcinoma

doi:10.4251/wjgo.v17.i4.101371

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (170)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

HTML

100

Figures (1-3)

Tables (1-4)

Sum=143

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=17

Apr 15, 2025 (publication date) through Mar 28, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Apr 15, 2025; 17(4): 101371
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.101371

Full Size Figure Download Figure

Figure 1 Research flowchart. HCC: Hepatocellular carcinoma; PCT: Postoperative combined therapy; PSM: Propensity score matching; IPTW: Inverse probability of treatment weighting; TACE: Transcatheter arterial chemoembolization; PD-1: Programmed death 1; PD-L1: Programmed death ligand 1; VEGFR: Vascular endothelial growth factor receptor.

Citation: Lu JL, Cheng Y, Xu ZL, Qian GX, Wei MT, Jia WD. Immune checkpoint inhibitors plus anti-angiogenesis in patients with resected high-risk hepatitis B virus-associated hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(4): 101371
URL: https://www.wjgnet.com/1948-5204/full/v17/i4/101371.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i4.101371